Designing dual-labeling systems such as the Dre/Rox and Cre/LoxP systems [35] under the control of a Sftpc and Pd-l1 promoter appears to be a promising strategy to specifically target the IAAPs and examine their precise contribution to the AT2 lineage in the context of repair after injury, regeneration, or even in cancer. Here, SFTPC is linked to cancer.